CNS Pharmaceuticals

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOUSTON , Sept. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will present at the H.C.

CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Continued execution on clinical operations for potentially pivotal global trial evaluating Berubicin for the treatment of Glioblastoma Multiforme ("GBM")   Enrollment progressing with 23 clinical trial sites open to-date of the 54 sites selected across the U.S., Italy, France, Spain, and Switzerland, and European enrollment expected imminently HOUSTON , Aug. 15, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended June 30, 2022 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. "Within the past 6 months alone, we have executed on a number of clinical and operational advancements including expanding our global presence with clinical approvals in Spain, France and Switzerland to drive patient enrollment forward, as well as expanding eligibility for patients to participate in our potentially pivotal study of Berubicin for the treatment of GBM with our recently amended protocol, which was approved by the FDA, Swissmedic, National Agency for the Safety of Medicine and Health Products (ANSM) Competent Authority  and corresponding European ethics committees.

CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Company reiterates support of proposals for the authorization to increase number of shares available for issuance by the Company and authorization for the Board to effect a reverse stock split at their discretion Video to shareholders from John Climaco, CEO of CNS Pharmaceuticals now available on the Company's website HOUSTON , July 25, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today urged shareholders to vote in favor of the proposals outlined in the Company's Definitive Proxy Statement (the "Proxy")  for the upcoming Annual Shareholder Meeting to be held Wednesday, July 27, 2022. The proposals outlined in the Proxy include the authorization to increase the number of shares available for issuance by the Company and the authorization for the Board of Directors to effect a reverse stock split of the outstanding shares of the Company's common stock, at a split ratio of between 1-for-2 and 1-for-30 at their discretion.

CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022

Expanded eligibility for patients who have received multiple therapies as first line therapy for GBM Company continues to enroll patients for the trial with 19 clinical trial sites open to-date, and an additional 42 sites selected across the U.S., Italy, France, Spain, and Switzerland that will be initiated and enrolling soon Interim analysis of the trial when 30- 50% of subjects reach 6 months in study HOUSTON , June 23, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its ongoing potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine (Gleostine) administered after first line therapy for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer. "We are pleased to have received this positive response from the FDA and to continue driving the Berubicin clinical development program forward.

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

HOUSTON , June 8, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that Sigmund Hsu, MD, member of the Company's Scientific Advisory Board, presented an overview of its ongoing clinical trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The abstract titled "Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy," was presented in the Central Nervous System Tumors poster session by Dr. Hsu.

CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

HOUSTON , May 24, 2022 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will be participating at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference

HOUSTON , May 18, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract was accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting being held virtually and in Chicago, IL from June 3-7, 2022. Details of the accepted abstract are as follows: Abstract Title:                        Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy Abstract Number:                  TPS2083 Presenter:                                Sandra L.

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Recent approvals of potentially pivotal Berubicin Study into Switzerland, France, and Spain expected to significantly drive patient enrollment Opportunities for Berubicin to be used in additional oncology indications with significant unmet needs HOUSTON , May 16, 2022 /PRNewswire/ --   CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended March 31, 2022 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. "Since the start of 2022, we have significantly expanded our international presence with clinical approvals in Spain, France and Switzerland received for our potentially pivotal study of Berubicin for the treatment of GBM.

CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Continued advancement of global patient enrollment with Switzerland, France, and Spain approvals received for pivotal study of Berubicin HOUSTON , April 28, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has received approval from the Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority and from the CElm Provincial de Sevilla Ethics Committee in Spain for the Company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer. "We continue to build momentum in our potentially pivotal study of Berubicin, and importantly advance toward bringing a much needed treatment option to patients.

CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Aeterna Zentaris

American Resources Corp

- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the continuation of its Virtual Investor Spotlight Series to be held on Thursday, April 14, 2022. Access the full series of events here.

JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC

Live video webcast with moderated fireside chat with members from the CNS Pharmaceuticals management team and featuring Key Opinion Leader, Samuel A. Goldlust, MD, on Thursday, April 14th at 11:30 AM ET HOUSTON , April 12, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight event on Thursday, April 14 th at 11:30 AM ET.

CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event

Company continues to drive global patient enrollment in pivotal study of Berubicin HOUSTON , April 6, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has received approval from the National Agency for the Safety of Medicine and Health Products (ANSM) Competent Authority and from the People Protection Ethics Committee (EC) SUD-EST III (CPP Sud-Est III) in France for the Company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer. "Access to patients is the lifeblood of any clinical study and this approval, in the second most populous country in Europe, provides just that for our Berubicin trial.

CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Aditxt Inc

TD Holdings Inc

NextPlay Technologies

Penny stocks under $1 to watch in April 2022 The post Best Penny Stocks For April 2022? 4 Under $1 To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks For April 2022? 4 Under $1 To Watch Now

Company previously received approval from swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland for the study Execution of global patient enrollment continues to progress in pivotal study of Berubicin for the treatment of GBM, one of the most aggressive forms of brain cancer HOUSTON , April 5, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has received approval from Swissmedic, the Swiss Agency for Therapeutic Products, for the Company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM). With approvals now received from both swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland, and Swissmedic, the Company can proceed with site initiation and patient enrollment in Switzerland.

CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Live webcast fireside chat on Wednesday, March 30 th at 2:30 PM ET HOUSTON , March 23, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals will participate at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, taking place March 28-30, 2022. In addition to the Company's corporate presentation available on demand for registered attendees, Mr.

CNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

HOUSTON, March 9, 2022 /PRNewswire/ --  CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released a video to shareholders reiterating its operational and clinical progress for lead product candidate, Berubicin, and addressing recent share price activity. "The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals.

CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders

HOUSTON, March 3, 2022 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the year ended December 31, 2021 and provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. 2021 Key Highlights May 2021: Commenced patient enrollment in the potentially pivotal study (CNS-201) evaluating efficacy of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (rGBM), one of the most aggressive types of brain cancer; June 2021: FDA granted Fast Track Designation to CNS Pharmaceuticals for Berubicin for the treatment of recurrent GBM; September 2021: Dosed first group of patients with Berubicin in the potentially pivotal study for the treatment of GBM; December 2021: Received approval from "swissethics," the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland, for the Company's potentially pivotal study of Berubicin for the treatment of recurrent GBM; and January 6, 2022: Announced a $11.5M private placement, priced at-the-market under Nasdaq rules.

CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.

Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?

HOUSTON, Jan. 20, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will participate in the Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 11:00 AM ET. As part of the virtual event, the Company will provide a corporate presentation, followed by a moderated interactive Q&A session.

CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

HOUSTON, Jan. 10, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (CNS), announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules of 12,105,264 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 12,105,264 shares of common stock, at a purchase price of $0.95 per share of common stock (or pre-funded warrant) and associated warrant. The gross proceeds to CNS from the private placement were approximately $11.5 million, before deducting placement agent fees and other offering expenses payable by the Company.

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

HOUSTON, Jan. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

HOUSTON, Jan. 6, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (CNS), announced today that it has entered into securities purchase agreements with several institutional and accredited investors to issue, in a private placement priced at-the-market under Nasdaq rules, 12,105,264 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 12,105,264 shares of common stock, at a purchase price of $0.95 per share of common stock (or pre-funded warrant) and associated warrant, for expected gross proceeds to CNS of approximately $11.5 million, before deducting placement agent fees and other offering expenses payable by the Company. The warrants will have an exercise price of $0.82 per share of common stock, will be exercisable immediately upon issuance for a period of five years from the date of issuance.

CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Denison Mines

Comstock Mining

Check these penny stocks out today following big moves The post These Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Penny Stocks Exploded Today, Here's Why

Aptose Biosciences

Celularity

Celyad

Spruce Biosciences

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

5 Beaten-Down Biotech Bets to Bounce Back in 2022

After losing some value lately, a hammer chart pattern has been formed for CNS Pharmaceuticals, Inc. (CNSP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

News for CNS Pharmaceuticals Stock (CNSP)